Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jul;41(4):461-6.
doi: 10.1515/jpm-2012-0173.

Periconceptional use of folic acid and risk of miscarriage - findings of the Oral Cleft Prevention Program in Brazil

Camila Vila-Nova  1 , George L Wehby, Fernanda C Queirós, Hrishkesh Chakraborty, Temis M Félix, Norman Goco, Janet Moore, Eduardo V Gewehr, Lorene Lins, Carla M C Affonso, Jeffrey C Murray
Affiliations
Randomized Controlled Trial

Periconceptional use of folic acid and risk of miscarriage - findings of the Oral Cleft Prevention Program in Brazil

Camila Vila-Nova et al. J Perinat Med. 2013 Jul.

Abstract

Objective: We report on the risk of miscarriage with high- and low-dosage periconceptional folic acid (FA) supplementation from a double-blind randomized clinical trial for prevention of orofacial cleft recurrence in Brazil.

Methods: Women at risk of recurrence of orofacial clefts in their offspring were randomized into high (4 mg/day) and low (0.4 mg/day) doses of FA supplementation. The women received the study pills before pregnancy, and supplementation continued throughout the first trimester. Miscarriage rates were compared between the two FA groups and with the population rate.

Results: A total of 268 pregnancies completed the study protocol, with 141 in the 4.0-mg group and 127 in the 0.4-mg group. The miscarriage rate was 14.2% in the low-dose FA group (0.4 mg/day) and 11.3% for the high-dose group (4 mg/day) (P=0.4877). These miscarriage rates are not significantly different from the miscarriage rate in the Brazilian population, estimated to be around 14% (P=0.311).

Conclusions: These results indicate that high-dose FA does not increase miscarriage risk in this population and add further information to the literature on the safety of high FA supplementation for prevention of birth defect recurrence.

PubMed Disclaimer

Conflict of interest statement

Disclosure of interests

The authors have no conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. De-Regil LM, Fernandez-Gaxiola AC, Dowswell T, Pena-Rosas JP. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2010;(10) CD007950. - PMC - PubMed
    1. Wehby GL, Murray JC. Folic acid and orofacial clefts: a review of the evidence. Oral Dis. 2010;16(1):11–19. - PMC - PubMed
    1. Genisca AE, Frias JL, Broussard CS, Honein MA, Lammer EJ, Moore CA, et al. Orofacial clefts in the National Birth Defects Prevention Study, 1997–2004. Am J Med Genet A. 2009;149A(6):1149–1158. - PMC - PubMed
    1. Czeizel AE, Dudas I, Metneki J. Pregnancy outcomes in a randomised controlled trial of periconceptional multivitamin supplementation. Final report. Arch Gynecol Obstet. 1994;255(3):131–139. - PubMed
    1. Cecatti JG, Guerra GV, Sousa MH, Menezes GM. Abortion in Brazil: a demographic approach. Rev Bras Ginecol Obstet. 2010;32(3):105–111. - PubMed

Publication types